Tags

Type your tag names separated by a space and hit enter

Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review.
Int J Hematol Oncol Stem Cell Res. 2020 Apr 01; 14(2):130-139.IJ

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Many studies have been done on APL blood disorders and its treatment. These studies have shown different results. In this systematic article, we tried to review the effect of ATO therapy with or without ATRA and chemotherapy on DIC parameters (D-dimer, Prothrombin Time, Activated Partial Thrombin Time, Platelet count) in APL patients. The result of included studies demonstrated that although ATO can reduce the number of malignant cells in the bone marrow and peripheral blood, it does not have enough potential to attenuate the danger of high score DIC that is usual in APL patients and should be better to be used with other therapeutic methods.

Authors+Show Affiliations

Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32461798

Citation

Mohammadi Kanesbi, Mehdi, et al. "Blood Parameters in Treatment With Arsenic Trioxide in Acute Promyelocytic Leukemia: a Systematic Review." International Journal of Hematology-oncology and Stem Cell Research, vol. 14, no. 2, 2020, pp. 130-139.
Mohammadi Kanesbi M, Jarahi L, Keramati MR. Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review. Int J Hematol Oncol Stem Cell Res. 2020;14(2):130-139.
Mohammadi Kanesbi, M., Jarahi, L., & Keramati, M. R. (2020). Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review. International Journal of Hematology-oncology and Stem Cell Research, 14(2), 130-139.
Mohammadi Kanesbi M, Jarahi L, Keramati MR. Blood Parameters in Treatment With Arsenic Trioxide in Acute Promyelocytic Leukemia: a Systematic Review. Int J Hematol Oncol Stem Cell Res. 2020 Apr 1;14(2):130-139. PubMed PMID: 32461798.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review. AU - Mohammadi Kanesbi,Mehdi, AU - Jarahi,Lida, AU - Keramati,Mohammad Reza, PY - 2020/5/29/entrez PY - 2020/5/29/pubmed PY - 2020/5/29/medline KW - Acute promyelocytic leukemia KW - All-trans retinoic acid KW - Arsenic trioxide KW - Chemotherapy KW - Disseminated intravascular coagulation SP - 130 EP - 139 JF - International journal of hematology-oncology and stem cell research JO - Int J Hematol Oncol Stem Cell Res VL - 14 IS - 2 N2 - Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Many studies have been done on APL blood disorders and its treatment. These studies have shown different results. In this systematic article, we tried to review the effect of ATO therapy with or without ATRA and chemotherapy on DIC parameters (D-dimer, Prothrombin Time, Activated Partial Thrombin Time, Platelet count) in APL patients. The result of included studies demonstrated that although ATO can reduce the number of malignant cells in the bone marrow and peripheral blood, it does not have enough potential to attenuate the danger of high score DIC that is usual in APL patients and should be better to be used with other therapeutic methods. SN - 2008-3009 UR - https://www.unboundmedicine.com/medline/citation/32461798/Blood_Parameters_in_Treatment_with_Arsenic_Trioxide_in_Acute_Promyelocytic_Leukemia:_A_Systematic_Review DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.